
	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Revenues	$	10,003	$	20,099	$	18,723	$	32,152
Costs and expenses:


Total Manufacture and Supply Expenses	4,561		4,526		8,213		8,915

R&D Project expenses:
Anaphylm project expenses	1,204		1,700		3,692		4,847
AQST-108 project expenses	190		—		385		789
Libervant project expenses	—		—		—		17
R&D other expenses:
Personnel costs1	2,218		2,039		4,350		3,743
Other2	493		423		1,039		698
Total Research and Development Expenses	4,105		4,162		9,466		10,094

Selling expenses:
Personnel costs3	608		254		1,302		1,186
Other4	2,912		814		5,174		955
Total Selling expenses	3,520		1,068		6,476		2,141

General & Administrative expenses:
Personnel costs5	5,176		4,918		10,016		9,579
Other6	4,009		5,370		15,285		10,325
Total General and Administrative Expenses	9,185		10,288		25,301		19,904

Total Selling, General and Administrative Expenses	12,705		11,356		31,777		22,045

Total costs and expenses	21,371		20,044		49,456		41,054
Loss from operations	(11,368)		55		(30,733)		(8,902)
Other income/(expenses), net	(2,180)		(2,800)		(5,745)		(6,671)
Net loss before income taxes	(13,548)		(2,745)		(36,478)		(15,573)

Net loss	$	(13,548)	$	(2,745)	$	(36,478)	$	(15,573)
Comprehensive loss	$	(13,548)	$	(2,745)	$	(36,478)	$	(15,573)

1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance

2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees

3 - Selling Personnel costs include payroll expenses and severance

4 - Other Selling expenses include commercialization and other related expenses

5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance

6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs